Technical Data
G2019F
Gastric Inhibitory Polypeptide (GIP)
Description:
Human gastric inhibitory polypeptide (GIP) is a 42aa peptide belonging to the glucagon-secretin family of peptide hormones. It is secreted by endocrine cells in the duodenal mucosa and stimulates glucose-dependent insulin secretion as well as GLP-1 release from more distal endocrine (L) cells in the intestinal mucosa. GIP shows amino-acid sequence similarities to glucagon, GLP-1 and GLP-2 (from ~50% identity for glucagon to 30% identity for GLP-2).

Applications:
Suitable for use in ELISA and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
ELISA: 1:2000; Using glutaraldehyde-linked GIP-OA (molar ratio 4:1) coated at 1ug/ml (or GIP coated directly at 2ug/ml). G2019F binds free GIP in solution.
Optimal dilutions to be determined by the researcher.

Hybridoma:
Sp2/mIL-6 myeloma cells with spleen cells from NMRI x Balb/c mice.

Culture Medium:
RPMI 1640 with 10% fetal calf serum

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
MabIgG1,k6F106Affinity Purified
SizeStorageShippingSourceHost
100ul-20°CBlue IceHumanMouse
Concentration:
~1mg/ml
Immunogen:
Synthetic human gastric inhibitory polypeptide
Purity:
Purified by Protein A/G affinity chromatography.
Form
Supplied as a liquid in PBS, pH 7.4, 15mM sodium azide. Also available without azide. See G2019F1.
Specificity:
Recognizes human Gastric Inhibitory Polypeptide (GIP). Binds free GIP in solution. Crossreacts up to 10% with PACAP and human GLP-2. < 0.1% crossreactivity with glucagon, GLP-1 and VIP.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.